BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6508033)

  • 1. Evaluation of prognostic characteristics of stage I cutaneous malignant melanoma.
    Tan GJ; Baak JP
    Anal Quant Cytol; 1984 Sep; 6(3):147-54. PubMed ID: 6508033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
    Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
    Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Survival analysis in patients with cutaneous malignant melanoma].
    Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
    Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acral lentiginous melanoma: histopathological prognostic features of 121 cases.
    Phan A; Touzet S; Dalle S; Ronger-Savlé S; Balme B; Thomas L
    Br J Dermatol; 2007 Aug; 157(2):311-8. PubMed ID: 17596173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, histological and quantitative prognostic factors in cutaneous malignant melanoma.
    Karjalainen J; Eskelinen M; Kosma VM; Lipponen P; Tuominen L; Alhava E
    Anticancer Res; 1992; 12(5):1507-11. PubMed ID: 1444213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Independent prognostic importance of vascular invasion in nodular melanomas.
    Straume O; Akslen LA
    Cancer; 1996 Sep; 78(6):1211-9. PubMed ID: 8826942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases.
    de Almeida LS; Requena L; Rütten A; Kutzner H; Garbe C; Pestana D; Gomes MM
    Am J Dermatopathol; 2008 Jun; 30(3):207-15. PubMed ID: 18496419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.
    Barnhill RL; Fine JA; Roush GC; Berwick M
    Cancer; 1996 Aug; 78(3):427-32. PubMed ID: 8697387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear morphometry of MIB-1 positive and negative tumor cells in primary and metastatic malignant melanoma of the skin.
    Karbowniczek M; Chosia M; Domagała W
    Pol J Pathol; 1999; 50(4):235-41. PubMed ID: 10721263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.
    Eigentler TK; Buettner PG; Leiter U; Garbe C;
    J Clin Oncol; 2004 Nov; 22(21):4376-83. PubMed ID: 15514379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant melanoma in Turkey: a single institution's experience on 475 cases.
    Tas F; Kurul S; Camlica H; Topuz E
    Jpn J Clin Oncol; 2006 Dec; 36(12):794-9. PubMed ID: 17060409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
    Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
    Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
    Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G
    Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for melanoma in children and adolescents: a clinicopathologic, single-center study of 137 Patients.
    Paradela S; Fonseca E; Pita-Fernández S; Kantrow SM; Diwan AH; Herzog C; Prieto VG
    Cancer; 2010 Sep; 116(18):4334-44. PubMed ID: 20549825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma.
    Hazan C; Melzer K; Panageas KS; Li E; Kamino H; Kopf A; Cordon-Cardo C; Osman I; Polsky D
    Cancer; 2002 Aug; 95(3):634-40. PubMed ID: 12209757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
    Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
    Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly clark level, affects pathologic staging of primary cutaneous melanoma.
    Murali R; Hughes MT; Fitzgerald P; Thompson JF; Scolyer RA
    Ann Surg; 2009 Apr; 249(4):641-7. PubMed ID: 19300224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.